Sight Sciences, Inc. (SGHT)

Sight Sciences' stock has experienced fluctuations, with a 124.29% increase over the last 12 months but a -20.81% year-to-date return as of late January 2026. In January 2026, the company announced preliminary financial highlights for Q4 and full-year 2025, reporting expected Q4 revenue between $20.3 million and $20.4 million and full-year revenue between $77.3 million and $77.4 million. Also in January 2026, an insider sale by the Chief Technology Officer was reported. In November 2025, Sight Sciences reported its Q3 2025 financial results, raised its full-year revenue guidance, reduced its adjusted operating expense guidance, and appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer. In August 2025, the company announced a reduction in force expected to yield approximately $12.0 million in annualized savings.

Sight Sciences experiences some demand seasonality, with a slight decrease in demand in the third quarter compared to the second quarter, followed by higher seasonality in the fourth quarter.

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing surgical and non-surgical technologies for treating eye diseases. The company's product portfolio includes the OMNI Surgical System, a therapeutic technology for reducing intraocular pressure in glaucoma patients; the SION Surgical Instrument, a bladeless device used in ophthalmic surgery; and the TearCare System, a dry eye device for localized heat therapy to treat evaporative dry eye disease due to meibomian gland dysfunction.

Sight Sciences is headquartered in Menlo Park, California, and primarily offers its products in the United States through sales representatives and distributors to hospitals, medical centers, and eyecare professionals. The OMNI Surgical System also has a CE Mark, indicating its availability or planned availability in European markets.

Sight Sciences generally holds a positive reputation among analysts, with a consensus "Buy" rating. However, the company faces challenges such as increasing competition in minimally invasive glaucoma surgery, slow advancements in insurance coverage for its TearCare product, and concerns about high quarterly cash burn rates.

Individual investors hold the largest share of Sight Sciences, Inc., accounting for approximately 30% of the company, while institutional investors hold about 25% of the stock. Major institutional shareholders include Kck Ltd., Long Focus Capital Management, Llc, and BlackRock, Inc. The company's CEO, Paul Badawi, is a significant individual shareholder, owning 11% of outstanding shares. Other notable holders include Allegro Investment Inc. and KCK Group.